Gene editing for hepatitis b: researchers track Long-Term safety

NCT ID NCT07254208

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study monitors 45 people with chronic hepatitis B who already received the experimental gene editing treatment PBGENE-HBV in an earlier trial. Researchers will watch for any delayed side effects over time. No new treatment is given; the goal is to understand the long-term safety of this gene editing approach.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HBV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • ICS ARENSIA Exploratory Medicine SRL

    Chisinau, Moldova, 2025, Moldova

  • Massachusetts General Hospital/Harvard University

    Boston, Massachusetts, 02114, United States

  • New Zealand Clinical Research

    Auckland, New Zealand, 1010, New Zealand

  • Queen Mary Hospital, University of Hong Kong

    Hong Kong, Hong Kong, Hong Kong